Please Wait...

Grünenthal Selects BioClinica OnPoint Clinical Trial Management System

– Leading Pain Management Company Standardizes on BioClinica CTMS Technology –

March 5, 2012

March 5, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Grünenthal GmbH has signed a global license agreement for BioClinica OnPoint CTMS to support its ongoing clinical trials. BioClinica OnPoint CTMS helps clinical trial sponsors to easily consolidate their data, share this data and improve trial management by using Microsoft SharePoint 2010 and Microsoft Office 2010.

Grünenthal selected BioClinica OnPoint after a thorough evaluation of the leading enterprise-scale CTMS solutions. The assessment team was comprised of Grünenthal experts from various functional areas. The workshops demonstrated that the requirements specified by Grünenthal could be delivered faster and most cost-effectively using OnPoint. Grünenthal was particularly impressed with BioClinica's ability to integrate with other clinical systems, the extensibility of this consolidated data via SharePoint-based dashboards and the fact that OnPoint allows clinical staff to do much of their work within the familiar environment of Microsoft Office applications.

"After careful review of the commercially available CTMS solutions, we felt that BioClinica's platform provides our clinical staff with a timely and comprehensive overview of relevant data and thus helps to make planning more efficient," said Hazel Collie, Head of Quality & Systems at Grünenthal. "In this regard, OnPoint supports our objective to enhance our innovation process, allowing us to develop solutions to improve the quality of life of our patients."

"Life sciences companies of all sizes face increased pressure to efficiently manage clinical trials while bringing drugs to market quickly," said Andrea McGonigle, managing director, Life Sciences, Microsoft Corp. "BioClinica uses Microsoft SharePoint and Office to help clients gain a comprehensive, real-time view into trial performance and act on that information."

Mark Weinstein, CEO of BioClinica, said, "We are proud to be selected to support Grünenthal's clinical trial support needs, world-wide. This agreement demonstrates the results of our continuing commitment to deliver innovative technology solutions that help customers execute and manage their clinical trials with greater efficiency and speed."

About the Grünenthal Group
The Grünenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company and to be a leader in therapy innovation. Altogether, the Grünenthal Group has affiliates in 30 countries worldwide. Grünenthal products are sold in more than 150 countries and approx. 4,500 employees are working for the Grünenthal Group globally. In 2010, Grünenthal reached revenues of about 910M €. For more information: www.grunenthal.com.

About Bioclinica

Bioclinica is a global life sciences solution provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval.  The company’s cloud-based offerings include medical imaging; cardiac safety; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site payments and forecasting; pharmacovigilance; trial management; and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers an integrated App xChange partner ecosystem, a global network of research sites, patient recruitment services, and post-approval research expertise to provide committed, detail-focused service through all stages of drug development.  The company’s thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.

Learn more about Bioclinica and our Clinical Adjudication and other offerings at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Great advice from our Dir. Cardiovascular Imaging on how to achieve top quality imaging acquisitions & assessments… https://t.co/P57970FrOf
bioclinica (18 hours ago)
RT @CenterWatch: #CWWeekly: The increasing trend of adopting digital health and #mhealth apps for patient care. Read more, https://t.co/wo9…
bioclinica (19 hours ago)
RT @CenterWatch: Examining the difference between #patient engagement & patient recruitment. Read more in #CWPulse by @AshleyTointon, https…
bioclinica (19 hours ago)
RT @CenterWatch: How can #socialmedia play a role in health disparities and #clinicaltrial patient recruitment? Read more in #CWPulse by @A…
bioclinica (19 hours ago)
RT @RAPSorg: What New @FDAcdrhIndustry Guidance is Coming in FY 2018: Alternative 510(k) Pathway and More | #Regulatory Recon https://t.co/…
bioclinica (19 hours ago)
RT @RAPSorg: .@US_FDA Finalizes Guidance on Promotional Drug Labeling and Ads | #Regulatory Focus https://t.co/2rmtTWajlf #FDA #pharma
bioclinica (19 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices